Third-generation antibody drug conjugates for cancer therapy--a balancing act

Ther Deliv. 2016;7(3):141-4. doi: 10.4155/tde-2016-0002.
No abstract available

Keywords: ADC; antibody-targeted drug delivery; cancer therapy; payload; site-specific conjugation.

Publication types

  • Editorial

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Breast Neoplasms / drug therapy
  • Brentuximab Vedotin
  • Enzymes / metabolism
  • Female
  • Half-Life
  • Humans
  • Immunoconjugates / pharmacokinetics
  • Immunoconjugates / therapeutic use*
  • Immunotherapy
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Maytansine / analogs & derivatives
  • Maytansine / therapeutic use
  • Neoplasms / drug therapy
  • Neoplasms / therapy*
  • Pharmaceutical Preparations / chemistry
  • Pharmaceutical Preparations / metabolism
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Enzymes
  • Immunoconjugates
  • Pharmaceutical Preparations
  • Maytansine
  • Brentuximab Vedotin
  • Trastuzumab
  • Ado-Trastuzumab Emtansine